* Ventyx Biosciences Inc VTYX.OQ VTYX.O is expected
to show no
change in quarterly revenue when it reports results on February
24 (estimated) for the period ending December 31 2024
*
* LSEG's mean analyst estimate for Ventyx Biosciences Inc
is for
a loss of 54 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Ventyx
Biosciences Inc is $12.50, above its last closing price
of $1.66.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 -0.50 -0.52 -0.50 Beat 3.4
Jun. 30 2024 -0.57 -0.58 -0.45 Beat 22.2
Mar. 31 2024 -0.68 -0.69 -0.62 Beat 9.7
Dec. 31 2023 -0.91 -0.90 -0.79 Beat 12.5
Sep. -0.89 -0.90 -0.92 Missed -2.7
30 2023
Jun. 30 2023 -0.72 -0.71 -0.91 Missed -28
Mar. 31 2023 -0.65 -0.65 -0.68 Missed -5
Dec. 31 2022 -0.67 -0.63 -0.62 Beat 0.8
This summary was machine generated February 21 at 21:24 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)